Point72 Asset Management’s Turnstone Biologics TSBX Stock Holding History

Point72 Asset Management’s Portfolio TSBX Stock Details TSBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-816,923	Closed	-$293K	–	2686
2025 Q2	$293K	Sell	816,923 -62,010	-7%	-$21.7K	﹤0.01%	1916
2025 Q1	$360K	Sell	878,933 -55,431	-6%	-$23.6K	﹤0.01%	1709
2024 Q4	$464K	Buy	934,364 +2,138	+0.2%	+$1.06K	﹤0.01%	1680
2024 Q3	$519K	Sell	932,226 -186,362	-17%	-$286K	﹤0.01%	1601
2024 Q2	$2.93M	Sell	1,118,588 -65,300	-6%	-$187K	0.01%	987
2024 Q1	$3.1M	Buy	1,183,888 +350,555	+42%	+$1M	0.01%	1119
2023 Q4	$2.12M	Hold	833,333	–	–	0.01%	1185
2023 Q3	$3.28M	Buy	+833,333	New	+$7.43M	0.01%	1012

Point72 Asset Management's TSBX Position: Q3 2025 in Review

Point72 Asset Management sold out of Turnstone Biologics (TSBX) in Q3 2025, closing a stake of 816,923 shares — an estimated $293K sold.

Point72 Asset Management first reported a position in TSBX in Q3 2023 and held it in 8 quarters. The position peaked at $3.28M in Q3 2023. 1 fund tracked by Wall St. Rank holds TSBX as of Q3 2025.

Point72 Asset Management reported no remaining Turnstone Biologics position as of Q3 2025 after selling out during the quarter.
Point72 Asset Management sold 816,923 Turnstone Biologics shares in Q3 2025, an estimated $293K.
Point72 Asset Management first reported a position in Turnstone Biologics in Q3 2023 and held it in 8 quarters.
Point72 Asset Management's Turnstone Biologics position peaked at $3.28M in Q3 2023.
1 fund tracked by Wall St. Rank held Turnstone Biologics as of Q3 2025.

Based on Point72 Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.